CN101182539A - Construction method of DC-SIGN promoter luciferase reporting plasmid - Google Patents

Construction method of DC-SIGN promoter luciferase reporting plasmid Download PDF

Info

Publication number
CN101182539A
CN101182539A CNA2007101565038A CN200710156503A CN101182539A CN 101182539 A CN101182539 A CN 101182539A CN A2007101565038 A CNA2007101565038 A CN A2007101565038A CN 200710156503 A CN200710156503 A CN 200710156503A CN 101182539 A CN101182539 A CN 101182539A
Authority
CN
China
Prior art keywords
sign
promoter
plasmid
basic
promotor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007101565038A
Other languages
Chinese (zh)
Inventor
吴南屏
许利军
靳昌忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Priority to CNA2007101565038A priority Critical patent/CN101182539A/en
Publication of CN101182539A publication Critical patent/CN101182539A/en
Pending legal-status Critical Current

Links

Images

Abstract

The invention discloses a construction method of the DC-SIGN promoter luciferase reported plasmid. By constructing the DC-SIGN promoter segment and the recombinant eucaryon of the luciferase reported vector p GL3-Basic, plasmid DC-Promoter-Pgl3-Basic is expressed and the plasmid expression and activity identification in Hela, Hacat, Wish and HuVEC cell strains; the invention successfully constructs the DC-promoter-pGL3-Basic DC-SIGN promoter luciferase reported plasmid. With the expression and luciferase activity identification in Hela, Hacat, Wish and HuVEC cell strains, the DC-SIGN promoter is proven to express different activities in different cell strains; the activities in the cell strains of HaCat and Hela are comparatively high.

Description

The construction process of DC-SIGN promoter luciferase reporting plasmid
Technical field
The invention belongs to technical field of molecular biology, relate to the construction process of DC-SIGN promoter luciferase reporting plasmid.
Background technology
DC-SIGN is a DCs surface important function molecule, plays an important role in the immunity of organism process.By the antigen presentation effect of DCs, DC is presented to virus, bacterium and the protozoon of organism infection around the effector cell, by directly and indirectly killing and wounding of effector cell, and the immunization of performance body, thus eliminate or suppress to infect the pathogenic micro-organism of body.In this process, the DC-SIGN that is positioned at the DC surface plays central role.The position is known up till now, and DC-SIGN is the acceptor of multiple pathogenic micro-organism, comprises HIV, HCV, CMV, SARS, dengue fever virus, Ebola virus, tubercule bacillus, intestinal bacteria core composition, leishmania or the like.
With HIV is example, DC-SIGN can with the combination of HIV-gp120 albumen high-affinity, this avidity is higher than the intermolecular avidity of HIV-gp120-CD4.DC-SIGN is by identification, combination and carry the HIV particle, and the HIV virion is transported to the secondary draining lymph node at position, place from the periphery infection site, infects the T cell in lymphatic node, thereby further virus is propagated to whole body.In this process, the DC-HIV-CD4+ cell forms a combination, this combination, and the distance of spatially furthered HIV and CD4+T cell, it is involutory that the acceptor of the part of HIV and CD4+T cell is easy to, and increased the chance of CD4+T cell infection.In addition, HIV can also and TLR (the Toll Like Receptor) combination on DCs surface, by the reaction in TLR downstream, make the DCs secrete cytokines, raise the expression of DC-IGN.This explanation DC-SIGN not only is subjected to the regulating effect of internal factor in the expression of DC cell, also is subjected to the influence of extraneous factor.
In external expression model, DC-SIGN mainly is subjected to IL-4 effect regulation and control.From the isolating mononuclearcell of human peripheral, through the combined stimulation of IL-4 and GM-CSF, the perhaps cell strain THP-1 in blood system source, Jurknt etc. are through the stimulation of IL-4 and PMA, can make the active DC-SIGN of these cell expressings, express model as DC-SIGN external.And in vivo, DC-SIGN only shows on the DCs of SM some kind of epiderm skin, and locates at enteron aisle lymphoglandula and placenta etc., expresses limitation relatively.
At eukaryotic cell, gene expression regulation mechanism relative complex, still, the promotor of gene still plays a major role in the expression of gene regulation and control.The DC-SIGN gene promoter area has significance for virus infection, therefore, we at first separate the DC-SIGN gene promoter, and be structured in the luciferase reporting carrier, transfection Hela, Hacat, Wish and HuVEC cell strain by the determination of activity of luciferase, are investigated the activity of DC-SIGN promotor respectively, the biology characteristics of research DC-SIGN are inquired into DC-SIGN expression mechanism and the meaning of DC-SIGN promotor in DC-SIGN expression process.
Summary of the invention
The objective of the invention is: the construction process that DC-SIGN promoter luciferase eucaryon reporter plasmid is provided.
The construction process of DC-SIGN promoter luciferase reporting plasmid of the present invention may further comprise the steps:
(1) with reference to the DC-SIGN promoter sequence of GeneBank AF209479, the a pair of primer of design DC-SIGN promotor, introduce Mlu I and Bgl II recognition site respectively at 5 ' end and 3 ' end: ACGCGT and AGATCT, with PCR method high-fidelity amplification DC-SIGN promoter fragment, and purified pcr product, standby:
(2) DC-SIGN promoter fragment and its expression vector pGL3-basic are carried out double digestion respectively, and the enzyme behind the purifying is cut product connect, connect product and transform DH-5 α competent cell, choose single white colony amplification, the extracting recombinant plasmid dna is made double digestion and is identified.
The a pair of primer sequence of above-mentioned DC-SIGN promotor is as follows:
Sense primer:ATCATACGCG TATGAGTCCT TCTCCCTGTC, contain Mlu I restriction enzyme site:
Antisense primer:TGTAAGATCT GTCACCCCAC TCTCCCCCAG contains Bgl II restriction enzyme site.
Description of drawings
Fig. 1 is the structure iron of pGL3-basic and pGL3-control.
Fig. 2 is DC-SIGN promotor amplification figure, and DNA marker is 100bp marker.
Fig. 3 is the sequence signature figure of DC-SIGN promotor.
Fig. 4 cuts figure as a result for the DC-SIGN-promoter-pGL3-Basic enzyme.The left side the 1st swimming lane is 200bp DNA ladder, the
2 swimming lanes are the contrast of DC-SIGN promoter PCR product, and the 3-7 swimming lane is DC-SIGN-promoter-pGL3-Basic double digestion result, and the 8th swimming lane is pGL3-Basic double digestion result, and the 9th swimming lane is λ/Hind III DNA ladder.
Fig. 5 is that the DC-SIGN promotor gets relative reactivity figure in obstructed cell.
Embodiment
1. make up the DC-SIGN promoter luciferase reporting plasmid
1.1 amplification DC-SIGN promotor
Get normal people's peripheral blood, separate PBMC, use the promotor of PCR primer amplification DC-SIGN gene.Used upstream primer is sense primer::ATC ATA CGC GTA TGA GTC CTT CTC CCT GTC, contain Mlu I restriction enzyme site, antisense primer:TGT AAG ATC TGT CAC CCC ACT CTC CCC CAG contains Bgl II restriction enzyme site.Use the Platinum_Taq DNA Polymerase High Fidelity of Invtrigon, the PCR reaction system is as follows:
5×PCRbuffer 2.5mM dNTP mix 50mM MgSO4 10mM sense primer 10mM antisense primer High Fidelity Taq(2U/μL) DNA(1ng/μL) DdH2O 10μL 4μL 2μL 2μL 2μL 0.5μL 1μL 28.5μL
Total volumes 50μL
Increase on the PCR instrument by following program
1. 95℃×3min
2. 94℃×20sec
58℃×30sec
72 ℃ * 25sec is totally 30 circulations
3. 72℃×5min
44 ℃ of preservations
1.2 PCR product purification
Used the post centrifugation method, operation steps and method are carried out according to product description
1.3 make up the DC-SIGN promoter luciferase reporting plasmid
After the pGL3-basic plasmid increases through intestinal bacteria DH-5 α, use plasmid a small amount of extraction agent box to carry out extracting, the operation by specification carries out.Gained PCR is through Bgl II and Mlu double digestion with the gained plasmid with in 1.1 then, and used restriction endonuclease gets restriction endonuclease for Takara company, and system is as follows:
A. B
10×Buffer H 4μl 10×Buffer H 4μl
Bgl II(10U/μl) 1μl Bgl II(10U/μl) 1μl
Mlu(10U/μl) 1μl Mlu(10U/μl) 1μl
PGL3-Basic/Enhancer(0.1ug/μl) 10μl DC-SIGN promoter(50ng/μl) 20μl
ddH2O 24μl ddH2O 14μl
total volume 40μl total volume 40μl
With the light mixing of above-mentioned system, centrifugal, 37 ℃ of enzymes are cut and are spent the night.Enzyme is cut product and is carried out electrophoresis at 1% sepharose, and the electrophoretic voltage size is according to must be apart from setting between two electrodes of horizontal strip electrophoresis groove, and size is 5V/cm, after electrophoresis finishes, carries out dna gel and reclaims.Then the gained purifying being got DC-SIGN promoter fragment (40ng/ μ l) is connected with the T4 ligase enzyme with pGL3-Basic plasmid cleavage fragment (80ng/ μ l):
10×T4 ligation Buffer pGL3-Basic DC-SIGN promoter T4 ligase(5U/μl) ddH2O 1.0μl 3.0μl 1.0μl 1.5μl 3.5μl
Total volume 10μl
With the said mixture mixing, centrifugal, 16 ℃ of reactions 3 hours.
Import competent cell 1.4 will connect product
Make and be divided in DH-5 α competent cell 100 μ l in the sterilization Ep pipe as on ice, operation as follows then with preparing solution with the single stage method competent cell in advance:
(1) competent cell precooling 20min on ice
(2) the connection product of adding 5 μ l in competent cell, mixing was placed 30 minutes on ice gently
Heat-shocked 90sec in (3) 42 ℃ of water baths placed 20 minutes immediately on ice
(4) add the nonresistant LB substratum of 800 μ l
(5) 37 ℃ of 200rpm shook 1 hour in horizontal constant temperature shaking table
(6) 4000rpm is centrifugal 5 minutes, removes 800 μ l supernatants
(7) with remaining 100 μ l liquid and precipitation mixing, be evenly coated on the LB solid culture flat board that contains penbritin (100 μ g/mL)
(8) earlier flat board is just being put 30min in 37 ℃ of bacteriological incubators, the bottom surface makes progress then, and bacterium faces down, 37 ℃ of overnight incubation.
(9) picking mono-clonal bacterium colony is put in 3mL and contains in the LB substratum of penbritin, vibrates 12-16 hour at 37 ℃ with 300rpm
(10) extract plasmid, carry out PCR and double digestion and identify
(11) will increase through identifying the LB that the bacterium liquid contain correct clone is put in 300mL (containing 100 μ g/mL)
(12) use the high-purity plasmid extraction test kit extracting DC-promoter-pGL3-Basic of amount in the plasmid
1.5 extracting DC-promoter-pGL3-Basic
(1) balance liquid EQ balance plasmid extraction Filter column
(2) with the centrifugal 5min of 300mL bacterium liquid 8000rpm, thoroughly remove supernatant
(3) add Lysis Buffer, thorough mixing, room temperature is placed 5min
(4) add among the neutralizer N buffer and 5min, 13000rpm high speed centrifugation 15min
(5) carefully get supernatant, add, filter, collect and filter gained liquid with balanced Filter column
(6) Virahol of adding 70% volume in the filter liquide of collecting, mixing
(7) the 13000rpm high speed centrifugation is 15 minutes, carefully removes supernatant
(8) 70% washing with alcohol precipitate once, and high speed centrifugation 10min carefully removes ethanol then
(9) will precipitate wind in the drying instrument to half-dried
(10) add ddH2O 400 μ L and melt plasmid
1.6 plasmid DC-SIGN-promoter-pGL3-Basic (DSPGB) transfecting eukaryotic cells
(1) transfection the day before yesterday, use to contain antibiotic culture medium culturing cell invariably, and by 0.6 * 104cell/ hole, inoculating cell is to 96 orifice plates
(2) plasmid is by 0.2 μ g/ hole (about 2 μ L), Opti-MEM reduced medium is by the standard in 25 μ L/ holes, with the ddH2O of 2 μ L as blank, 2 μ LpGL3-basic empty carriers are as negative control, 2 μ LDSPGB, with 2 μ LpGL3-control as positive control, be diluted among the Opti-MEM reduced medium mixing respectively
(3) Lipofectamine 2000 Transfection Reagent are diluted among the Opti-MEM of 25 μ L incubated at room 5min by the consumption in 0.5 μ L/ hole
(4) the Lipofectamine 2000 Transfection Reagent with dilution add among plasmid-Opti-MEM, mixing gently, incubated at room 20 minutes
(5) inhale the substratum that removes 96 well culture plate cells, add the Lipofectamine 2000-plasmid mixture book of 50 μ L, horizontal direction is shaken gently, makes the liquid mixture of adding be uniformly distributed in the culture plate bottom
Inhale after (6) 6 hours and remove aforesaid liquid, add ordinary culture medium
(7) hatched 30 hours at the cell cultures box column, detect the fluorescein activity then
1.7 uciferase activity detects
Detected uciferase activity in 30 hours after the transfection, carry out according to the following steps: (at room temperature carrying out)
(1) with Bright-Glo Luciferase buffer and Bright-Glo Luciferase substrate mixing, make Bright-GloLuciferase Assay reagent, packing, place-80 ℃ standby
(2) reagent among the Bright-Glo Luciferase Assay reagent melts from-80 ℃ of taking-ups, places 30min in room temperature
(3) cell is taken out from incubator, place 5min, inhale and go cells and supernatant in the culture plate,, remove PBS with PBS washing 1-2 time in room temperature
(4) add 100 μ LBright-Glo Luciferase Assay reagent,
(5) level vibration Glo Lysis Buffer guarantees that Bright-Glo Luciferase Assay reagent covers the diapire all cells several times
(6) incubated at room 5min
(7) detect at Orion II microplate luminometer, every hole detection time is 5sec
Interpretation of result:
1.DC-SIGN the amplification of promotor
The result of pcr amplification is carried out electrophoresis on 2% sepharose, the dna fragmentation size of gained is 237bp, as shown in Figure 1;
2.DC-SIGN the structure of promotor report carrier
Behind DC-SIGN promotor and pGL3-Basic double digestion, connect, behind the connection product transformed into escherichia coli, extract plasmid, carry out enzyme and cut evaluation, result such as Fig. 3;
3.DC-SIGN gene promoter active result's in obstructed cell mensuration
We find, the DC-SIGN promotor is relative higher with the activity in the Hela cell at Hacat, and active relatively low in HuVEC and Wish, this explanation, the DC-SIGN promotor is in different cells, different expression activities is arranged, and this expression activity may be relevant with intracellular microenvironment.Compare with the pGL3-control that contains the SV40 promotor, DC-SIGN promotor reporter gene produces to such an extent that uciferase activity is much lower.
Conclusion:
We have successfully made up the DC-SIGN promoter luciferase reporting plasmid, and it is imported respectively among Hela, HaCat, Wish and the HuVEC304, detect by uciferase activity, discovery is the expression activity difference in different cell strains, and expression activity is relative higher in the Hela cell strain of the HaCat in epidermic cell source and epithelial origin.
Sequence table
sense primer:ATCATACGCG TATGAGTCCT TCTCCCTGTC
antisense primer:TGTAAGATCT GTCACCCCAC TCTCCCCCAG

Claims (2)

1.DC-SIGN the construction process of promoter luciferase reporting plasmid is characterized in that following step:
(1) with reference to the DC-SIGN promoter sequence of GeneBank AF209479, the a pair of primer of design DC-SIGN promotor, introduce Mlu I and Bgl II recognition site respectively at 5 ' end and 3 ' end: ACGCGT and AGATCT, with PCR method high-fidelity amplification DC-SIGN promoter fragment, and purified pcr product, standby;
(2) DC-SIGN promoter fragment and its expression vector pGL3-basic are carried out double digestion respectively, and the enzyme behind the purifying is cut product connect, connect product and transform DH-5 α competent cell, choose single white colony amplification, the extracting recombinant plasmid dna is made double digestion and is identified.
2. according to the construction process of the described DC-SIGN promoter luciferase reporting plasmid of claim 1, it is characterized in that a pair of primer sequence of described DC-SIGN promotor is as follows:
sense primer:ATCATACGCG TATGAGTCCT TCTCCCTGTC
antisense primer:TGTAAGATCT GTCACCCCAC TCTCCCCCAG
CNA2007101565038A 2007-11-06 2007-11-06 Construction method of DC-SIGN promoter luciferase reporting plasmid Pending CN101182539A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA2007101565038A CN101182539A (en) 2007-11-06 2007-11-06 Construction method of DC-SIGN promoter luciferase reporting plasmid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2007101565038A CN101182539A (en) 2007-11-06 2007-11-06 Construction method of DC-SIGN promoter luciferase reporting plasmid

Publications (1)

Publication Number Publication Date
CN101182539A true CN101182539A (en) 2008-05-21

Family

ID=39447962

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101565038A Pending CN101182539A (en) 2007-11-06 2007-11-06 Construction method of DC-SIGN promoter luciferase reporting plasmid

Country Status (1)

Country Link
CN (1) CN101182539A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102257009A (en) * 2008-10-21 2011-11-23 杜门蒂斯有限公司 Ligands that have binding specificity for dc-sign

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102257009A (en) * 2008-10-21 2011-11-23 杜门蒂斯有限公司 Ligands that have binding specificity for dc-sign

Similar Documents

Publication Publication Date Title
CN107384894B (en) Functional graphene oxide efficiently delivers method of the CRISPR/Cas9 for gene editing
CN108486108A (en) It is a kind of knock out people's HMGB1 genes cell strain and its application
CN107893076A (en) CRISPR Cas9 targeting knock outs human breast cancer cell RASSF2 genes and its specific sgRNA
ATE221917T1 (en) DNA CONSTRUCTS AND THEIR USE FOR TRANSFECTION OF CELLS BY HOMOLOGOUS RECOMBINATION
CN108315330A (en) The sgRNA and knockout technique of CRISPR-Cas9 systemic characteristics targeting people's RSPO2 genes and application
CN108004270A (en) Utilize the method for luciferase reporter gene detection duck IFN-β promoter activity
Lutz et al. Viral ubiquitin ligase stimulates selective host microRNA expression by targeting ZEB transcriptional repressors
CN114561354A (en) Method for improving killing activity of NK (natural killer) cells
CN101182539A (en) Construction method of DC-SIGN promoter luciferase reporting plasmid
CN106497973B (en) A kind of mankind and other mammalian cells adhere to body expression vector, expression system, preparation method and application
CN103275981B (en) Promoter for filamentous fungal protein secretion pressure feedback regulation element and feedback inhibition resistance, plasmid, preparation method and transformed cell
CN105624162A (en) Small interfering RNA, short hairpin RNA and vector aimed at R-Spondin2 gene target spot of mammal, as well as application of small interfering RNA, short hairpin RNA and vector
US20220193189A1 (en) USE OF Dvl3-DEP PEPTIDE IN PREPARATION OF MEDICAMENT FOR REPAIRING SERTOLI CELL INJURY IN TESTES
CN104762285A (en) Lyase of self-cleaving escherichia coli, and applications thereof
CN106811485A (en) BANCR gene overexpressions slow virus carrier, BANCR slow virus and construction method and application
CN103173480A (en) Method for screening multidrug resistance related microRNA (ribonucleic acid) by using dual-luciferase report genes
CN102796706B (en) Cell model having TLR4 immune response function and method for constructing same
CN103505745A (en) Application of micromolecule RNA used as immunosuppressor
AU7529000A (en) Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes
CN101182540A (en) Construction method of DC-SIGN promoter eucaryon plasmid deleting NF-kB site
Premadasa et al. Selenium-Dependent Read Through of the Conserved 3’-Terminal UGA Stop Codon of HIV-1 nef
CN103757024B (en) A kind of tiny RNA and application thereof disturbing TLR4 acceptor
CN102816739B (en) Method for maintaining pluripotency of embryonic stem cell (MEC) by using truncated type c-Jun and applications
CN102337266B (en) siRNAs and recombinant vector for inhibiting expression of Nogo A, MAG and OMgp genes, and application of siRNAs and recombinant vector
Inclan-Rico et al. MrgprA3 neurons selectively control myeloid-derived cytokines for IL-17 dependent cutaneous immunity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080521